PHS Stock Chart & Stats
€6.29
-€0.02(-0.30%)
At close: 4:00 PM EST
€6.29
-€0.02(-0.30%)
Day’s Range― - ―
52-Week Range€4.33 - €6.71
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€136.80M
Enterprise Value€1.49K
Total Cash (Recent Filing)€259.54M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)17.7
Beta0.40
Next Earnings
Jul 29, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding27,120,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Photocure ASA News
PHS FAQ
What was Photocure ASA’s price range in the past 12 months?
Photocure ASA lowest stock price was €4.33 and its highest was €6.71 in the past 12 months.
What is Photocure ASA’s market cap?
Photocure ASA’s market cap is €136.80M.
When is Photocure ASA’s upcoming earnings report date?
Photocure ASA’s upcoming earnings report date is Jul 29, 2026 which is in 2 days.
How were Photocure ASA’s earnings last quarter?
Photocure ASA released its earnings results on May 07, 2026. The company reported -€0.043 earnings per share for the quarter, missing the consensus estimate of >-€0.001 by -€0.042.
Is Photocure ASA overvalued?
According to Wall Street analysts Photocure ASA’s price is currently Overvalued.
Does Photocure ASA pay dividends?
Photocure ASA does not currently pay dividends.
What is Photocure ASA’s EPS estimate?
Photocure ASA’s EPS estimate is <0.01.
How many shares outstanding does Photocure ASA have?
Photocure ASA has 27,120,820 shares outstanding.
What happened to Photocure ASA’s price movement after its last earnings report?
Photocure ASA reported an EPS of -€0.043 in its last earnings report, missing expectations of >-€0.001. Following the earnings report the stock price went down -0.825%.
Which hedge fund is a major shareholder of Photocure ASA?
Currently, no hedge funds are holding shares in DE:PHS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Photocure ASA
Photocure ASA is a specialized pharmaceutical enterprise focused on the development, manufacturing, commercialization, and distribution of medicinal products. Its operational footprint extends across multiple European nations, including the Nordic region, Germany, France, Austria, the United Kingdom, the Netherlands, and Italy, in addition to the United States. The company's primary offering, Hexvix/Cysview, aids in the identification and ongoing management of bladder cancer. Moreover, Photocure is actively progressing Cevira, a therapeutic agent in development targeting human papilloma virus (HPV) infections and pre-cancerous lesions of the cervix. The firm distributes its products to pharmaceutical wholesalers, pharmacies, and healthcare institutions through collaborative licensing arrangements. Founded in 1993, Photocure ASA maintains its corporate headquarters in Oslo, Norway.
PHS Company Deck
PHS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear commercial momentum with solid product revenue growth (9% Q4; 10% full-year ex-FX), meaningful unit gains (North America +13% units, rigid +19%), stronger commercial EBITDA and an improving installed base and account penetration (active accounts +22%). Strategic partnerships (Richard Wolf, ForTec, Claritas/ISC) and a healthy cash position support future growth and M&A ambitions. Offsetting these positives were timing-related revenue headwinds from the absence of 2024 milestones, a decline in operating cash flow, one-time COGS adjustments, FX headwinds, earn-out and buyback cash outflows, and uncertainty around regulatory approvals and CMS reimbursement timing. Overall, the positive operational and strategic developments significantly outweigh the near-term financial and timing challenges.View all DE:PHS earnings summariesTechnical Analysis
Photocure ASA
―
―
Eagle Pharmaceuticals
―
Omeros
―
Tonix Pharma
―
Oncolytics Biotech
―
Pfizer
―